Brought to you by 
Madrigal nets $282.7mm via FOPO
08 Jun 2018
Executive Summary
Madrigal Pharmaceuticals Inc. (developing therapies for cardiovascular, metabolic, and liver diseases) netted $282.7mm through the follow-on public offering of 983,607 common shares at $305 each. Stockholders sold an additional 363,625 shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Madrigal nets $282.7mm via FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice